RAP 0.00% 20.5¢ resapp health limited

Ann: AstraZeneca to use new ResApp software in clinical study, page-30

  1. 1,268 Posts.
    lightbulb Created with Sketch. 587
    they spending way more than they will generate in revenue is the point - another iron in the fire = the fire that consumes the limited resources it has - I would have thought one of these various avenues RAP goes into would produce some decent shorter term revenue - otherwise its an R&D company and will need way more $$$ before being cashflow break even
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.